

**BIOADAPTIVES, INC.  
CONSOLIDATED BALANCE SHEETS**

	<b>December 31, 2017</b>	<b>December 31, 2016</b>
	<u>          </u>	<u>          </u>
<b>ASSETS</b>		
Current Assets:		
Cash	\$ 360	\$ 7,635
Inventory	-	135,274
Marketable securities	3,203	3,648
Total Current Assets	<u>3,563</u>	<u>146,557</u>
 Furniture and Fixtures, net	 -	 -
<b>TOTAL ASSETS</b>	<b>\$ <u>3,563</u></b>	<b>\$ <u>146,557</u></b>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
Current Liabilities:		
Accounts payable	58	2,600
Accrued liabilities - related party	-	43,361
Advance from Ferris Holding, Inc. - related party	-	276,956
Total Current Liabilities	<u>58</u>	<u>322,917</u>
 Total Liabilities	 <u>58</u>	 <u>322,917</u>
Stockholders' Deficit:		
Preferred stock, (\$.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)	-	-
Common stock (\$.0001 par value, 100,000,000 shares authorized; 15,578,262 and 14,180,456 shares issued and outstanding as of December 31, 2017 and 2016, respectively)	1,559	1,419
Additional paid-in capital	3,115,273	2,872,604
Accumulated other comprehensive loss	(58,336)	(57,891)
Accumulated deficit	<u>(3,054,991)</u>	<u>(2,992,492)</u>
Total Stockholders' Deficit	<u>3,505</u>	<u>(176,360)</u>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b>	<b>\$ <u>3,563</u></b>	<b>\$ <u>146,557</u></b>

The accompanying notes are an integral part of these consolidated financial statements.

**BIOADAPTIVES, INC.**  
**CONSOLIDATED STATEMENTS**  
**OF OPERATIONS AND COMPREHENSIVE LOSS**

	<b>Year Ended December 31,</b>	
	<b>2017</b>	<b>2016</b>
Revenues	\$ 3,735	\$ 19,044
Cost of revenue	1,818	9,128
<b>Gross Profit</b>	1,917	9,916
<b>Operating Expenses</b>		
Depreciation	-	527
General and administrative	64,036	160,783
Professional fees	380	19,954
<b>Total Operating Expenses</b>	64,416	181,264
<b>Operating Loss</b>	(62,499)	(171,348)
<b>Net Loss</b>	\$ (62,499)	\$ (171,348)
<b>Other Comprehensive Loss, net of tax</b>		
Unrealized loss on marketable securities	(445)	(1,216)
<b>Other Comprehensive Loss</b>	(445)	(1,216)
<b>Comprehensive Loss</b>	(62,944)	(172,564)
<b>Net Loss Per Common Share: Basic and Diluted</b>	\$ (0.00)	\$ (0.01)
<b>Weighted Average Number of Common Shares Outstanding: Basic and Diluted</b>	14,525,155	14,002,842

The accompanying notes are an integral part of these consolidated financial statements.

**BIOADAPTIVES, INC.**  
**CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT**

	Preferred stock		Common stock		Additional paid-in capital	Accumulate d Deficit	Accumulated Other Comprehensive Loss	Total
	Shares	Amount	Shares	Amount				
<b>Balance, December 31, 2015</b>	-	\$ -	12,736,436	\$ 1,275	\$ 2,673,170	\$ (2,821,144)	\$ (56,675)	\$ (203,374)
Share-based compensation	-	-	-	-	55,176	-	-	55,176
Purchase of Inventory	-	-	1,444,020	144	144,258	-	-	144,402
Net change in unrealized gain on marketable securities	-	-	-	-	-	-	(1,216)	(1,216)
Net loss for the period	-	-	-	-	-	(171,348)	-	(171,348)
<b>Balance, December 31, 2016</b>	-	\$ -	14,180,456	\$ 1,419	\$ 2,872,604	\$ (2,992,492)	\$ (57,891)	\$ (176,360)
Share-based compensation	-	-	-	-	5,182	-	-	5,182
Common stock issued for service	-	-	200,000	20	33,980	-	-	34,000
Common stock issued for related party debt	-	-	1,197,806	120	203,507	-	-	203,627
Net change in unrealized gain on marketable securities	-	-	-	-	-	-	(445)	(445)
Net loss for the period	-	-	-	-	-	(62,499)	-	(62,499)
<b>Balance, December 31, 2017</b>	-	\$ -	15,578,262	\$ 1,559	\$ 3,115,273	\$ (3,054,991)	\$ (58,336)	\$ 3,505

The accompanying notes are an integral part of these consolidated financial statements.

**BIOADAPTIVES, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

	<b>Year Ended December 31,</b>	
	<b>2017</b>	<b>2016</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net loss	\$ (62,499)	\$ (171,348)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	-	527
Stock-based compensation	34,000	-
Stock-based compensation - related party	5,182	55,176
Changes in operating assets and liabilities:		
Inventory	1,818	9,128
Deposit	-	1,700
Accounts payable	(2,542)	92,390
Accrued liabilities – related party	23,501	18,000
Net Cash Provided By (Used In) Operating Activities	(540)	5,573
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Advances from related party	1,500	4,913
Payment on advances from related party	(8,235)	(2,950)
Net Cash Provided By (Used In) Financing Activities	(6,735)	1,963
Net change in cash	(7,275)	7,536
Cash at beginning of period	7,635	99
Cash at end of period	\$ 360	\$ 7,635
<b>SUPPLEMENTAL CASH FLOW INFORMATION:</b>		
Cash paid for income taxes	\$ -	\$ -
Cash paid for interest	\$ -	\$ -
<b>NON CASH INVESTING AND FINANCING ACTIVITIES</b>		
Settlement of liabilities by related party	\$ -	\$ 124,144
Unrealized loss on investments in marketable securities	\$ 445	\$ 1,216
Purchase of inventory by common shares	\$ -	\$ 144,402
Common stock issued for related party debt	\$ 203,627	\$ -

The accompanying notes are an integral part of these consolidated financial statements.

BioAdaptives, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business – BioAdaptives, Inc. (formerly known as APEX 8 Inc.) (“BioAdaptives”, “Company”) was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages.

On September 11, 2013, BioAdaptives incorporated Blenders Choice Inc (“Blenders”) in Nevada. Blenders is a 100% owned subsidiary and was created as a separate sales and marketing organization. BioAdaptives has elected to manage its sales through independent distributors and has suspended operations of Blenders Choice.

On September 1, 2014, the Company entered into a License Agreement (“Agreement”) with Ferris Holding, Inc. (“Ferris”). The Agreement gives the Company the right to use Ferris’s proprietary processes and trade secrets, including its stem cell enhancement products. In consideration for these rights, the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement is twelve (12) months.

On September 1, 2014, the Company entered into a Sub-License Agreement (“Sub-License”) with Essence International, Ltd. (“Essence”). The Sub-License gives Essence the right to use proprietary processes and trade secrets, including its stem cell enhancement products which were obtained by the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement is twelve (12) months

2. SUMMARY OF SIGNIFICANT POLICIES

Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Blenders Choice Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.”

Use of estimates – The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash and cash equivalents – Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days. Cash equivalents are placed with high credit quality financial institutions and are primarily in money market funds. The carrying value of those investments approximates fair value. As of December 31, 2017 and 2016, the Company has no cash equivalents.

Investment Securities - Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.

In accordance with Accounting Standards Codification (“ASC”) 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate

that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.

Earnings (loss) per share – Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. There were no potentially dilutive securities outstanding during the periods presented.

Revenue recognition - According to ASC 605, the Company recognize revenue when persuasive evidence of an arrangement exists, delivery of products has occurred, the sales price is fixed or determinable and collectability is reasonably assured. For our Company, this generally means that we recognize revenue when title to our products is transferred to resellers or other customers.

Inventory - Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at December 31, 2017 and 2016, the Company determined that no reserve was required.

Stock-based compensation – The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with BioAdaptives, Financial Accounting Standards Board ("FASB") ASC 718-10, Compensation – Stock Compensation, and the conclusions reached by FASB ASC 505-50, Equity – Equity-Based Payments to Non-Employees. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.

Fair value of financial instruments – As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 ("ASC 820-10"), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:

- Level 1      Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
- Level 2      Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
- Level 3      Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Pursuant to ASC 825, Financial Instruments, the fair value of cash, marketable securities and stock based compensation is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

Assets measured at fair value on a recurring basis were presented on the Company's balance sheet as of December 31, 2017.

**Fair Value Measurements as of December 31, 2017 Using:**

	<b>Total Carrying Value as of December 31, 2017</b>	<b>Quoted Market Prices in Active Markets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>
<b><u>Assets:</u></b>				
Equity Securities	\$ 3,203	\$ 3,203	\$ -	\$ -
Total	\$ 3,203	\$ 3,203	\$ -	\$ -

Equity securities at December 31, 2017, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of \$3,203 (\$0.0303 per share).

Assets measured at fair value on a recurring basis were presented on the Company's balance sheet as of December 31, 2016.

**Fair Value Measurements as of December 31, 2016 Using:**

	<b>Total Carrying Value as of December 31, 2016</b>	<b>Quoted Market Prices in Active Markets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>
<b><u>Assets:</u></b>				
Equity Securities	\$ 3,648	\$ 3,648	\$ -	\$ -
Total	\$ 3,648	\$ 3,648	\$ -	\$ -

Equity securities at December 31, 2016, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of \$3,648 (\$0.0345 per share).

**Concentration of credit risk** – Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings.

**Advertising costs** - Advertising costs are anticipated to be expensed as incurred and advertising costs of \$106 and \$46,047 were included in general and administrative expenses for the year ended December 31, 2017 and 2016.

**Income taxes** – The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes requires a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a more-likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company's experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives.

The Company recorded valuation allowances on the net deferred tax assets. Management will reassess the realization of deferred tax assets based on the accounting standards for income taxes each reporting period. To the extent that the

financial results of operations improve and it becomes more likely than not that the deferred tax assets are realizable, the Company will be able to reduce the valuation allowance.

Significant judgment is required in evaluating the Company's tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.

#### Recent Accounting Pronouncements

### 3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of \$3,054,991 as of December 31, 2017. The Company requires capital for its contemplated operational and marketing activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

### 4. STOCKHOLDERS' EQUITY

Preferred Stock – The Company is authorized to issue 5,000,000 shares of \$.0001 par value preferred stock. As of December 31, 2017 and 2016, no shares of preferred stock had been issued.

Common Stock – The Company is authorized to issue 100,000,000 shares of \$.0001 par value common stock. As of December 31, 2017 and 2016, there were 15,578,262 and 14,180,456 shares of the Company's common stock issued and outstanding, respectively.

On October 3, 2017, the Company issued 1,197,806 shares of common stock to Ferris Holding, Inc. a common control entity for the settlement of debt valued at \$203,627.

On October 3, 2017, the Company issued 200,000 shares of common stock to 2 unrelated parties for services valued at \$34,000.

On February 15, 2016, the Company issued 1,444,020 shares of common stock to Ferris Holding, Inc. a common control entity for the purchase of inventory valued at \$144,402.

In the year ended December 31, 2015, the Company issued 100,000 shares of common stock to its chief executive officer, Christopher G. Hall, as compensation for two year of services to be performed pursuant to an employment agreement dated February 6, 2015. The Company valued the 100,000 shares of common stock on the date of the agreement, \$1.10 per share, which resulted in a total consideration of \$110,050 which will be expensed throughout the two year term of the employment agreement. As of December 31, 2017 and 2016, the Company expensed \$5,182 and \$55,176, respectively.



## 5. RELATED PARTY TRANSACTIONS

On June 1, 2014, the Company entered into a rental agreement with Ferris for the corporate office. Monthly rent is \$1,500. The term of the lease is month to month.

Advances from Ferris Holding, Inc., the controlling shareholder of the Company, may be non-interest bearing, unsecured and due on demand. During the year ended December 31, 2017 and 2016, \$0 and \$124,144 in expenses were paid by Ferris Holding, Inc on behalf of the Company. During the year ended December 31, 2017 and 2016, the Company received cash advance of \$1,500 and \$4,913 from Ferris Holding, Inc and repaid \$8,235 and \$2,950 to Ferris Holding Inc. On October 3, 2017, the Company sold all inventories of \$133,472 to Ferris Holding Inc. and the amount was paid by reducing advances from Ferris Holding , Inc and the Company repaid all remaining debts owed to Ferris Holding Inc. of \$203,627 with 1,197,806 shares of common stock.

As of December 31, 2017 and 2016, the Company had advances from Ferris Holdings, Inc. – related party balance of \$0 and \$150,849, respectively.

As of December 31, 2017 and 2016, the Company had a rent payable due to Ferris in the amount of \$0 and \$43,361, respectively, which is included in our accrued liabilities – related party balance in our consolidated balance sheets.

On February 6, 2015, the Company entered into a two (2) year employment agreement with its chief executive officer, Christopher G. Hall, whereby the Company issued 100,000 shares of restricted common stock as compensation for two (2) years of executive services to be performed. The shares were valued at the closing share price of \$1.10 on the date of the agreement. This resulted in compensation expense of \$110,050 being amortized over the two (2) year term of the employment agreement.

## 6. PROVISION FOR INCOME TAXES

The Company provides for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”) resulting in significant modifications to existing law. The Company has completed the accounting for the effects of the Act during the quarter ended December 31, 2017. The Company’s financial statements for the year ended December 31, 2017 reflect certain effects of the Act which includes a reduction in the corporate tax rate from 34% to 21% as well as other changes.

The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 34% to the net loss before provision for income taxes for the following reasons:

	<u>December 31, 2017</u>	<u>December 31, 2016</u>
Income tax expense at statutory rate	\$ (21,250)	\$ (58,258)
Effect of change in statutory rate	397,149	
Valuation allowance	<u>(375,899)</u>	<u>58,258</u>
Income tax expense per books	<u>\$ -</u>	<u>\$ -</u>

Net deferred tax assets consist of the following components as of:

	<u>December 31, 2017</u>	<u>December 31, 2016</u>
NOL Carryover	\$ (641,548)	\$ (1,017,447)
Valuation allowance	<u>641,548</u>	<u>1,017,447</u>
Net deferred tax asset	<u>\$ -</u>	<u>\$ -</u>

Due to the change in ownership provisions of the Income Tax laws of United States of America, net operating loss carry forwards of approximately \$3,055,000 for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.